Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971185 · ClinicalTrials.gov registry record
A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
A clinical trial of Myelodysplastic Syndromes (MDS), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 430
- Enrollment target
- 1
- Study location
NCT06971185: Active study of Myelodysplastic Syndromes (MDS), sponsored by Bristol-Myers Squibb.
NCT06971185 is a study of Myelodysplastic Syndromes (MDS) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 430 participants, above the 147-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (193% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06971185, a study of Myelodysplastic Syndromes (MDS), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 430 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
Conditions Studied
Interventions
- DRUG Luspatercept
- DRUG Erythropoiesis-stimulating agent (ESA)
Study Locations (1)
New Jersey
- Bristol Myers Squibb - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2025-08-01 |
What the registry record for NCT06971185 still lists
NCT06971185 is an observational study that tracks outcomes without assigning an intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 147-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (193% higher).
The record links to 1 condition, with Myelodysplastic Syndromes (MDS) appearing as the primary indexed condition, and to 2 interventions - of which Luspatercept is the first listed.
NCT06971185 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06971185 about?
NCT06971185 is a clinical study titled "A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept". The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
What is the current status of trial NCT06971185?
This trial is currently active not recruiting. The enrollment target is 430 participants. The study started on 2024-11-22. Estimated completion is 2025-08-01.
What conditions does trial NCT06971185 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes (MDS).
What interventions are being tested in trial NCT06971185?
The interventions under investigation include: Luspatercept (DRUG), Erythropoiesis-stimulating agent (ESA) (DRUG).
Who is sponsoring clinical trial NCT06971185?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06971185 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06971185's enrollment target sits among peer trials
430 2nd of 10 the highest of 10 other Myelodysplastic Syndromes (MDS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes (MDS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RECRUITING · Phase 3
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
RECRUITING · NA
-
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI